Efficacy

Kisqali (Ribociclib) Efficacy in Breast Cancer

Kisqali, also known by its generic name ribociclib, is a targeted therapy approved for the treatment of certain types of breast cancer. Specifically, it is used in combination with an aromatase inhibitor for the treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer as initial endocrine-based therapy. Clinical trials have demonstrated that Kisqali, in combination with letrozole, significantly improves progression-free survival (PFS) compared to letrozole alone. The MONALEESA-2 trial, a pivotal phase III study, showed that the addition of Kisqali to letrozole reduced the risk of disease progression or death by 44% in postmenopausal women with HR+/HER2- advanced breast cancer.

Furthermore, Kisqali has been studied in premenopausal women when combined with an aromatase inhibitor or fulvestrant. The MONALEESA-7 trial, which focused on premenopausal or perimenopausal women, found that ribociclib plus endocrine therapy significantly improved overall survival (OS) and PFS. These results establish Kisqali as an effective treatment option for a broader patient population, including younger women with HR+/HER2- advanced breast cancer.

Truqap (Capivasertib) Efficacy in Breast Cancer

Truqap, known generically as capivasertib, is an investigational drug that targets the AKT signaling pathway, which is often dysregulated in cancers, including breast cancer. Although not yet approved, capivasertib has shown promise in clinical trials for the treatment of breast cancer, particularly in patients with AKT pathway alterations. In early-phase studies, capivasertib has demonstrated antitumor activity in patients with advanced breast cancer, including those with triple-negative breast cancer (TNBC), a subtype that lacks targeted therapies and has a poor prognosis.

One of the key studies evaluating the efficacy of capivasertib in breast cancer is the FAKTION trial, which investigated the addition of capivasertib to fulvestrant in patients with HR+/HER2- metastatic breast cancer. The results indicated a significant improvement in PFS for patients receiving the combination therapy, suggesting that capivasertib could provide a beneficial treatment option for patients with this subtype of breast cancer. Further clinical trials are ongoing to confirm these findings and to explore the efficacy of capivasertib in other combinations and settings within breast cancer treatment.